BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18489525)

  • 1. Prognostic factors in a prospective series of papillary renal cell carcinoma.
    Gontero P; Ceratti G; Guglielmetti S; Andorno A; Terrone C; Bonvini D; Faggiano F; Tizzani A; Frea B; Valente G
    BJU Int; 2008 Sep; 102(6):697-702. PubMed ID: 18489525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
    Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
    Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification.
    Pignot G; Elie C; Conquy S; Vieillefond A; Flam T; Zerbib M; Debré B; Amsellem-Ouazana D
    Urology; 2007 Feb; 69(2):230-5. PubMed ID: 17275070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma.
    Phuoc NB; Ehara H; Gotoh T; Nakano M; Yokoi S; Deguchi T; Hirose Y
    Urology; 2007 May; 69(5):843-8. PubMed ID: 17482919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers.
    Minervini A; Di Cristofano C; Gacci M; Serni S; Menicagli M; Lanciotti M; Salinitri G; Rocca CD; Lapini A; Nesi G; Bevilacqua G; Minervini R; Carini M
    J Urol; 2008 Oct; 180(4):1284-9. PubMed ID: 18707725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma.
    Wagner B; Patard JJ; Méjean A; Bensalah K; Verhoest G; Zigeuner R; Ficarra V; Tostain J; Mulders P; Chautard D; Descotes JL; de la Taille A; Salomon L; Prayer-Galetti T; Cindolo L; Valéri A; Meyer N; Jacqmin D; Lang H
    Eur Urol; 2009 Feb; 55(2):452-9. PubMed ID: 18692951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphological subtyping of papillary renal cell carcinoma: clinicopathological characteristics and prognosis.
    Yamashita S; Ioritani N; Oikawa K; Aizawa M; Endoh M; Arai Y
    Int J Urol; 2007 Aug; 14(8):679-83. PubMed ID: 17681054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
    Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
    BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma.
    Yoo C; Song C; Hong JH; Kim CS; Ahn H
    J Urol; 2008 Aug; 180(2):486-91; discussion 491. PubMed ID: 18550101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High nuclear Livin expression is a favourable prognostic indicator in renal cell carcinoma.
    Haferkamp A; Bedke J; Vetter C; Pritsch M; Wagener N; Buse S; Crnkovic-Mertens I; Hoppe-Seyler K; Macher-Goeppinger S; Hoppe-Seyler F; Autschbach F; Hohenfellner M
    BJU Int; 2008 Dec; 102(11):1700-6. PubMed ID: 18990137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus.
    Kim KH; You D; Jeong IG; Kwon TW; Cho YM; Hong JH; Ahn H; Kim CS
    BJU Int; 2012 Dec; 110(11 Pt B):E673-8. PubMed ID: 22973869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma.
    Margulis V; Tamboli P; Matin SF; Meisner M; Swanson DA; Wood CG
    J Urol; 2007 Nov; 178(5):1878-82. PubMed ID: 17868733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality.
    Mejean A; Hopirtean V; Bazin JP; Larousserie F; Benoit H; Chrétien Y; Thiounn N; Dufour B
    J Urol; 2003 Sep; 170(3):764-7. PubMed ID: 12913693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma.
    Djordjevic G; Mozetic V; Mozetic DV; Licul V; Ilijas KM; Mustac E; Oguic R; Fuckar Z; Jonjic N
    Pathol Res Pract; 2007; 203(2):99-106. PubMed ID: 17270362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma.
    Yildiz E; Gokce G; Kilicarslan H; Ayan S; Goze OF; Gultekin EY
    BJU Int; 2004 May; 93(7):1087-93. PubMed ID: 15142169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma.
    Klatte T; Pantuck AJ; Said JW; Seligson DB; Rao NP; LaRochelle JC; Shuch B; Zisman A; Kabbinavar FF; Belldegrun AS
    Clin Cancer Res; 2009 Feb; 15(4):1162-9. PubMed ID: 19228721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy.
    Klatte T; Seligson DB; LaRochelle J; Shuch B; Said JW; Riggs SB; Zomorodian N; Kabbinavar FF; Pantuck AJ; Belldegrun AS
    Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):894-900. PubMed ID: 19240241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma.
    Margulis V; Tamboli P; Matin SF; Swanson DA; Wood CG
    Cancer; 2008 Apr; 112(7):1480-8. PubMed ID: 18240184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: possible prognostic differences.
    Bedke J; Buse S; Pritsch M; Macher-Goeppinger S; Schirmacher P; Haferkamp A; Hohenfellner M
    BJU Int; 2009 May; 103(10):1349-54. PubMed ID: 19076147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma: Assessment of 241 patients with > 15-year follow-up.
    Lang H; Lindner V; de Fromont M; Molinié V; Letourneux H; Meyer N; Martin M; Jacqmin D
    Cancer; 2005 Feb; 103(3):625-9. PubMed ID: 15611969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.